Prognostic value of expression of nuclear factor kappa-B/p65 in non-GCB DLBCL patients

Wang, Jing; Zhou, Min; Zhang, Qiguo; Xu, Jingyan; Lin, Tong; Zhou, Rong-Fu; Li, Juan; Yang, Yonggong; Chen, Bing; Ouyang, Jian

doi:10.18632/oncotarget.14182

Cited by 10 publications

(8 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is consistent with the findings of Kloo et al, Kasama et al 2014 [5], Foureau et al 2015 [21], Hallas et al 2019 [22], Odqavist et al [23], who have shown that constitutive activation of NF-κB is a common feature of ABC DLBCL cells [24]. The expression of nuclear factor kappa B/p65 in diffuse large B-cell lymphoma ABC subtype was significantly higher than the GCB in the current study [11]. This study clarified the role of NFκB [p65] in ABC DLBCL and so aids in determining the subgroup of non-GCB DLBCL for which this pathway will serve as a valuable therapeutic target.…”

Section: Discussionsupporting

confidence: 92%

“…Although patients who expressed NFκB [p65] in this study had higher incidence of extranodal involvement, presented more in later stages [III + IV], and had higher LDH levels and IPI score, yet most of the patients had low ECOG score between 0 to 1. They suggested that that NFκB [p65] is an independent predictor of survival in high risk non-GCB DLBCL [11].…”

Section: Discussionmentioning

confidence: 99%

“…It's suggested that ABC-DLBCL is driven by an abnormally high NF-κB activity that deregulates expression of Bcl-2 family proteins, and is associated with inferior outcomes when compared to GCB-DLBCL [10]. Many publications have described p65 as an independent predictor of survival in high risk ABC DLBCL [11]. Constitutive NF-κB activation is due to several distinct genetic alterations in ABC-DLBCL.…”

Section: Nf-κb [Nuclear Factor Kappa-light-chain-enhancer Of Activatementioning

confidence: 99%

See 2 more Smart Citations

Diagnostic and Prognostic Value of Nuclear Factor Kappa-B in Diffuse Large B Cell Lymphoma in Egyptian Patients with Hepatitis C Virus Genotype 4

Halawani¹,

Sordi²,

Aiad³

et al. 2019

AJMB

View full text Add to dashboard Cite

Background: Members of the NFκB [p65] family have potential diagnostic and prognostic role in various inflammatory diseases and Lymphomas. Aim: We studied NFκB [p65] in paraffin blocks of hepatitis-C-virus [HCV] positive genotype-4 and HCV negative diffuse large B-cell lymphoma [DLBCL] patients, aiming at identification of its differential expression and prognosis in DLBCL and its subtypes; GCB and ABC. This is to establish its relation to HCV infection and its role in lymphogenesis. Besides assessing the role of new directly acting antiviral drugs [Sofusbuvir/Ledipasvir] concomitantly administered to [CHOP] combination in HCV positive DLBCL. Subjects and Methods: NFκB [p65] expression was assessed using Anti-NFκB [p65] antibody semi-quantitative technique in 30 newly diagnosed DLBCL patients [HCV positive [n = 15], HCV negative [n = 15]. Results: NFκB [p65] expression was higher in the HCV positive DLBCL patients than their HCV negative counterpart, with a positive correlation with the viral load [r = 0.536, p = 0.088]. NFκB [p65] expression was significantly more frequently detected in the ABC subtype than GCB subtype [p = 0.04]. Patients who expressed NFκB [p65] had higher incidence of extranodal involvement, advanced stages, higher LDH levels and IPI score. Besides, the expression of NFκB [P65] revealed an inferior overall response [OR] [p = 0.044]. Higher complete response rates to CHOP concomitantly with antiviral [ledipasvir/sofosbuvir] were encountered in the HCV positive group. In HCV positive group, NFκB [P65] displayed a positive relationship with the viral load and liver enzymes [p = 0.04], besides an inverse relation with serum albumin. This raises the possibility that NFκB [p65] expression is suggestive of the hepatic necro-inflammation in HCV pa-How to cite this paper: El tients. The ABC group presented more in advanced stages than GCB. Higher frequency of the ABC subgroup exhibited intermediate to high viral load, while it was less in the GCB. A statistically significant difference was found in the NFκB [p65] positive patients as regards MUM1 expression among the two groups [p ≤ 0.001]. Double positive [CD10+, MUM1+] and triple negative [CD10-, BCL6-, MUM1-] cases were encountered in the HCV positive group, and were characterized with a high NFκB [p65] expression. Conclusion: NFκB [p65] is expressed in patients with DLBCL, more frequently in ABC than in GCB subtypes. Expression of NFκB [p65] is associated with poor response to therapy in DLBCL. The NFκB [p65] disclosed an increased expression in HCV positive DLBCL compared to HCV negative group. The viral load displayed a positive correlation with the NFκB [p65] expression. Simultaneous administration of DAAs in combination with CHOP disclosed a better response and high tolerability.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 99%

Section: Nf-κb [Nuclear Factor Kappa-light-chain-enhancer Of Activatementioning

confidence: 99%

See 1 more Smart Citation

Diagnostic and Prognostic Value of Nuclear Factor Kappa-B in Diffuse Large B Cell Lymphoma in Egyptian Patients with Hepatitis C Virus Genotype 4

Halawani¹,

Sordi²,

Aiad³

et al. 2019

AJMB

View full text Add to dashboard Cite

show abstract

“…In addition, GCB DLBCLs were found to express genes of germinal center B cells, such as CD10, LMO2, or BCL6, and frequently, they were associated with REL amplification, EZH2 mutation, or t (14;18) translocation [3,[7][8][9][10][11][12][13]. The pathogenesis of ABC DLBCLs was believed to be related to activation of the NF-κB signaling pathway via the B-cell receptor (BCR) pathway, but recent studies demonstrated that NF-κB may be expressed in both ABC and GCB DLBCL subgroups and is an adverse prognostic factor [7,[12][13][14][15][16][17][18][19][20]. TNFAIP3, CARD11, CD79B, CD79A, TRAF2, MYD88, and REL are the most commonly altered genes with an adverse impact in the ABC DLBCL subtype [7,12,13,[17][18][19][20][21].…”

Section: Introductionmentioning

confidence: 99%

Tumor Microenvironment in Diffuse Large B-Cell Lymphoma: Role and Prognosis

Cioroianu

Stînga

Sticlaru

et al. 2019

Analytical Cellular Pathology

View full text Add to dashboard Cite

Diffuse large B-cell lymphoma (DLBCL) represents 30-40% of all non-Hodgkin lymphomas (NHL) and is a disease with an aggressive behavior. Because about one-third of DLBCL patients will be refractory or resistant to standard therapy, several studies focused on identification of new individual prognostic and risk stratification biomarkers and new potential therapeutic targets. In contrast to other types of cancers like carcinomas, where tumor microenvironment was widely investigated, its role in DLBCL pathogenesis and patient survival is still poorly understood, although few studies had promising results. The composition of TME and its interaction with neoplastic cells may explain the role of several genes (beta2-microglobulin gene, CD58 gene), receptor-like programmed cell death-1 (PD-1) and its ligand (PD-L1), or other cell components (Treg) in tumor evasion of immune surveillance, resulting in tumor progression. Also, it was found that “gene expression profile” of the microenvironmental cells, the phenotype of tumor-associated macrophages (TAM), the expression of matricellular proteins like SPARC and fibronectin, the overexpression of several types of matrix metalloproteinases (MMPs) like MMP-2 and MMP-9, or the tissue inhibitors of matrix metalloproteinases (TIMPs) may lead to a favorable or adverse outcome. With this review, we try to highlight the influence of microenvironment components over lymphoid clone progression and their prognostic impact in DLBCL patients.

show abstract

“…Under the stimulation of the above activators, IκBα is phosphorylated by the IκB kinase (IKK) and degraded via the ubiquitin-proteasome system. Then, the RelA/p50 dimers expose and translocate to the nucleus, leading to the transcription of target genes which may be involved in controlling cell cycle distribution and apoptosis occurrence 5,6 .…”

Section: Introductionmentioning

confidence: 99%

β-TrCP1 promotes cell proliferation via TNF-dependent NF-κB activation in diffuse large B cell lymphoma

Cai

Chen

Huang

et al. 2019

Cancer Biology & Therapy

View full text Add to dashboard Cite

Diffuse large B cell lymphoma (DLBCL), a heterogeneous group of invasive disease, is the most common type of B-cell non-Hodgkin's lymphomas. The mechanism of its development is closely related to the constitutive activation of NF-κB. In this study, we investigated the function and the mechanism of β-TRCP1 in DLBCL. CCK8 and EdU assays showed that β-TRCP1 could promote the growth of DLBCL cells under the stimulation of TNFα. Furthermore, overexpression of β-TRCP1 enhanced NF-κB activation in the presence of TNFα. Moreover, ectopic expression of β-TRCP1 decreased IκB-α expression but increased phospho-p65 expression. In addition, β-TRCP1 promoted cell cycle progression by accelerating G1-S phase transition. We also found that silencing of β-TrCP1 increased mitoxantrone-induced cell growth arrest and apoptosis. Based on these, we proposed that the expression of β-TRCP1 promoted cell proliferation via TNF-dependent NF-κB activation in DLBCL cells.

show abstract

Prognostic value of expression of nuclear factor kappa-B/p65 in non-GCB DLBCL patients

Cited by 10 publications

References 40 publications

Diagnostic and Prognostic Value of Nuclear Factor Kappa-B in Diffuse Large B Cell Lymphoma in Egyptian Patients with Hepatitis C Virus Genotype 4

Diagnostic and Prognostic Value of Nuclear Factor Kappa-B in Diffuse Large B Cell Lymphoma in Egyptian Patients with Hepatitis C Virus Genotype 4

Tumor Microenvironment in Diffuse Large B-Cell Lymphoma: Role and Prognosis

β-TrCP1 promotes cell proliferation via TNF-dependent NF-κB activation in diffuse large B cell lymphoma

Contact Info

Product

Resources

About